An article about our company appeared in Japan Chemical Daily

NATiAS aims to win major deal for oligonucleotide therapeutics CDMO

Article summary

NATiAS (Chuo-ku, Kobe), a CDMO (Contract Development and Manufacturing Organization) for oligonucleotide APIs in which Mitsui Chemicals, Toray Engineering, and other companies have invested, is developing a large-scale CDMO using a proprietary manufacturing method that is suitable for mass production and the company will begin to aim new projects. The company plans to launch a manufacturing facility that meets Good Manufacturing Practice (GMP) standards by the end of 2023. Using the partnership with Mitsui Chemicals in procuring raw materials, which has been an issue for the company, as a lever for growth, the company aims to obtain orders from major pharmaceutical companies for products under development for diseases that are estimated to affect tens of millions of patients worldwide. The company aims to capture a share of the oligonucleotide therapeutics CDMO market, which is expected to expand, by strengthening cooperation with companies receiving investments and business partners.

Click here for the official website of Japan Chemical Daily(in Japanese)